Read More

AstraZeneca Announced Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

AZN

Read More

Silicon Carbide Semiconductor Supplier Selected Aehr’s FOX System for Wafer Level Test and Burn-in of Silicon Carbide Devices for Automotive Electric Vehicles

Aehr Test Systems (NASDAQ: AEHR) today announced that a new customer has selected its FOX-PTM test and burn-in system to be used for qualification and production wafer level test and burn-in of their silicon carbide devices for automotive electric vehicles.

AEHR